Marksans Pharma Reports Highest Net Sales and Profit in Five Quarters for December 2024

Marksans Pharma has recently reported its financial results for the quarter ending December 2024, showcasing a notable performance within the Pharmaceuticals & Drugs industry. The company's score has undergone an adjustment in evaluation, reflecting a shift from 10 to 11 over the past three months.
The financial data reveals that Marksans Pharma achieved its highest net sales in the last five quarters, totaling Rs 681.85 crore. This positive trend is mirrored in the operating profit, which also reached a peak of Rs 138.77 crore for the same period. Additionally, profit before tax (PBT) and profit after tax (PAT) figures were recorded at Rs 115.41 crore and Rs 104.56 crore, respectively, both marking the highest levels in the last five quarters. The PAT has shown a growth rate of 20.5% compared to the average of the previous four quarters, indicating a solid performance in profitability.

However, it is important to note that the non-operating income has also reached its highest point at Rs 27.85 crore, raising questions about the sustainability of this income derived from non-business activities.

For more insights on Marksans Pharma's financial trends, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.